Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science
Copyright policy )Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science
)Department of Medicine,University of Cambridge School of Clinical Medicine,Cambridge, UKe-mail: jec1001@cam.ac.ukD. M. ReidUniversity of Aberdeen Medical School,Foresterhill,Aberdeen AB25 2ZD, UKJ. BoisdronHoffman-La Roche Ltd,Basle, SwitzerlandM.-L. BrandiMetabolic Bone Unit, Laboratory of Molecular Genetics,Department of Internal Medicine, University of Florence,Florence, ItalyN. BurletInternational Osteoporosis Foundation,Nyon, SwitzerlandD. CahallSanofi-Aventis,Bridgewater, NJ, USAP. D. DelmasUniversity of Lyon and INSERM Research Unit 831,Lyon, FranceW. DereAmgen,Thousand Oaks, CA, USAJ.-P. DevogelaerThe Arthritis Unit, Universite Catholique de Louvain,Brussels, BelgiumL. A. FitzpatrickMedicines Disease Center, GlaxoSmithKline,King of Prussia, PA, USAB. FlamionLaboratory of Physiology and Pharmacology,University of Namur,Namur, BelgiumN. GoelClinical Development, UCB Inc.,Smyrna, GA, USA
- University of Cambridge United Kingdom
- University of Lyon System France
- University of Cologne Germany
- Université Catholique de Louvain Belgium
- University of Liège Belgium
Drug Approval/methods, Male, Bone Density Conservation Agents/therapeutic use, Epidemiology, Glucocorticoids/adverse effects, Biomedische technologie en medicijnen, Sciences de la santé humaine, Osteoporosis/chemically induced/drug therapy/prevention & control, 618.97, Sex Factors, SDG 3 - Good Health and Well-being, Bone Density, 616, Humans, Human health sciences, Drug Approval, Glucocorticoids, Ziekenhuisstructuur en organisatie van de gezondheidszorg, Clinical Trials as Topic, Bone Density Conservation Agents, Farmacie(FARM), Bone Density/drug effects, Research Design, Osteoporosis, Female, Public Health, General & internal medicine, Médecine générale & interne, ddc: ddc:618.97
Drug Approval/methods, Male, Bone Density Conservation Agents/therapeutic use, Epidemiology, Glucocorticoids/adverse effects, Biomedische technologie en medicijnen, Sciences de la santé humaine, Osteoporosis/chemically induced/drug therapy/prevention & control, 618.97, Sex Factors, SDG 3 - Good Health and Well-being, Bone Density, 616, Humans, Human health sciences, Drug Approval, Glucocorticoids, Ziekenhuisstructuur en organisatie van de gezondheidszorg, Clinical Trials as Topic, Bone Density Conservation Agents, Farmacie(FARM), Bone Density/drug effects, Research Design, Osteoporosis, Female, Public Health, General & internal medicine, Médecine générale & interne, ddc: ddc:618.97
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).24 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!